Inglês – Tradução Livre 65/2013

TEXTO
Rio lab to produce Brazil’s first vaccine for export

Brazil’s Minister of Health, Alexandre Padilha, on Monday signed an agreement with the Bill and Melinda Gates Foundation for the production of a double vaccine against measles and rubella exclusively for export. The aim is for Brazil to export at least 30 million doses of the new vaccine in the coming years.

‘This partnership will lead to other vaccines being produced in Brazil, which will generate jobs and revenue for the country,’ said the minister.

The new vaccine will be produced by the laboratory Bio-Manguinhos, of the Oswaldo Cruz Foundation in Rio de Janeiro. Artur Couto, the head of the laboratory, says that the vaccine will be sold at low cost to the United Nations, which will then distribute it in developing nations in Africa, Asia and Latin America.

Currently, there is only one laboratory which produces this type of vaccine, based in India. Tests will begin in mid 2014 in four African countries, one of which will be Mozambique.

Bio-Manguinhos also produces the MMR (measles, mumps and rubella) vaccine, widely used in vaccination campaigns in Brazil. According to Padilha, measles and rubella were eradicated in Brazil following vaccination programs in 2000 and 2009 respectively.

http://www1.folha.uol.com.br/internacional/en/scienceandhealth/2013/10/1363681-rio-lab-to-produce-brazils-first-vaccine-for-export.shtml

Tradução Livre
Rio lab to produce Brazil’s first vaccine for export
Laboratório do Rio produz a primeira vacina do Brasil para exportação

Brazil’s Minister of Health, Alexandre Padilha, on Monday signed an agreement with the Bill and Melinda Gates Foundation for the production of a double vaccine against measles and rubella exclusively for export. The aim is for Brazil to export at least 30 million doses of the new vaccine in the coming years.
O Ministro da Saúde, Alexandre Padilha, na segunda-feira assinou um acordo com a “Bill e Melinda Gates Foundation” para a produção de uma vacina dupla contra sarampo e rubéola exclusivamente para exportação. A ajuda é para o Brasil exportar pelo menos 30 milhões de doses da nova vacina nos próximos anos.

‘This partnership will lead to other vaccines being produced in Brazil, which will generate jobs and revenue for the country,’ said the minister.
“Esta parceria leverá outros vacinas a serem produzidas no Brasil, o que gerará empregos e renda para o país”, disse o ministro.

The new vaccine will be produced by the laboratory Bio-Manguinhos, of the Oswaldo Cruz Foundation in Rio de Janeiro. Artur Couto, the head of the laboratory, says that the vaccine will be sold at low cost to the United Nations, which will then distribute it in developing nations in Africa, Asia and Latin America.
A nova vacina será produzida pelo laboratório Bio-Manguinhos, da Fundação Oswaldo Cruz no Rio de Janeiro. Artur Couto, o chefe do laboratório, diz que a vacina será vendida por baixo custo para as Nações Unidas, a qual será depois distribuída nas nações em desenvolvimento na África, Ásia e América Latina.

Currently, there is only one laboratory which produces this type of vaccine, based in India. Tests will begin in mid 2014 in four African countries, one of which will be Mozambique.
Atualmente, há somente um laboratório que produz este tipo de vacina, baseado na Índia. Testes começarão na metade de 2014 em quatro países africanos, um dos quais será Moçambique.

Bio-Manguinhos also produces the MMR (measles, mumps and rubella) vaccine, widely used in vaccination campaigns in Brazil. According to Padilha, measles and rubella were eradicated in Brazil following vaccination programs in 2000 and 2009 respectively.
Bio-Manguinhos também produz a vacina MMR (sarampo, caxumba e rubéola), amplamente usada nas campanhas de vacinação no Brasil. De acordo com Padilha, sarampo e rubéola foram erradicadas no Brasil seguindo os programas de vacinação em 2000 e 2009 respectivamente.